FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079571840> ?p ?o ?g. }

• W2079571840 endingPage "313" @default.
• W2079571840 startingPage "313" @default.
• W2079571840 abstract "Letters17 August 1999Reversal of Protease Inhibitor–Related Visceral Abdominal Fat Accumulation with Recombinant Human Growth HormoneStefan Mauss, MD, Eva Wolf, BSc, and Hans Jaeger, MDStefan Mauss, MD40211 Dueseldorf, Germany (Mauss)KIS-Curatorium for Immunodeficiency; Munich, Germany (Wolf)KIS-Curatorium for Immunodeficiency; Munich, Germany (Jaeger)Search for more papers by this author, Eva Wolf, BSc40211 Dueseldorf, Germany (Mauss)KIS-Curatorium for Immunodeficiency; Munich, Germany (Wolf)KIS-Curatorium for Immunodeficiency; Munich, Germany (Jaeger)Search for more papers by this author, and Hans Jaeger, MD40211 Dueseldorf, Germany (Mauss)KIS-Curatorium for Immunodeficiency; Munich, Germany (Wolf)KIS-Curatorium for Immunodeficiency; Munich, Germany (Jaeger)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-4-199908170-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A 35-year-old HIV-seropositive patient with a history of Pneumocystis carinii pneumonia, cytomegalovirus retinitis, and wasting developed an increase of abdominal girth while receiving antiretroviral treatment with stavudine, lamivudine, and indinavir. Gastrointestinal symptoms, including distention, fullness, bloating, and abdominal cramps, also developed. The symptoms did not respond to metoclopramide, cisapride, or butylscopolamine. Despite a switch to nelfinavir and then a regimen that did not contain any protease inhibitors (stavudine, didanosine, hydroxyurea, and nevirapine), the symptoms worsened.Before combination therapy with protease inhibitors started, the patient's weight had been 65 kg. Twenty-two months later, he had reached 81.5 kg; ...References1. Miller KD, Jones E, Jack A, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet. 1998;351:871-5. CrossrefMedlineGoogle Scholar2. Tanner J, Whitehouse R. The effect of human growth hormone on subcutaneous fat thickness in hyposomatotrophic and panhypopituitary dwarfs. Endocrinology. 1967;39:263-75. CrossrefGoogle Scholar3. Parra A, Argote RM, Garcia G, Cervantes C, Alatorre S, Péres-Paten E. Body composition in hypopituitary dwarfs before and during growth hormone therapy. Metabolism. 1979;28:851-7. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: 40211 Dueseldorf, Germany (Mauss)KIS-Curatorium for Immunodeficiency; Munich, Germany (Wolf)KIS-Curatorium for Immunodeficiency; Munich, Germany (Jaeger) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGrowth hormone and HIV infection: Contribution to disease manifestations and clinical implicationsA randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophyMetabolic complications of antiretroviral therapy in childrenHALS: HIV-assoziiertes LipodystrophiesyndromUse of recombinant human growth hormone in HIV-associated lipodystrophyLow-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot studyMetabolic Complications Associated with the Use of Highly Active Antiretroviral Therapy in HIV-1–Infected AdultsUpdate on HIV LipodystrophyEffects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected PatientsPharmacologic Therapy for HIV-Associated LipodystrophyLong-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapyHealth risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormoneHIV lipodystrophyEffects of Recombinant Human Growth Hormone on Fat Distribution in Patients with Human Immunodeficiency Virus–Associated WastingManagement of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society–USA PanelEffect of Recombinant Human Growth Hormone in the Treatment of Visceral Fat Accumulation in HIV InfectionMaintenance of Breast Size Reduction After Mastoplasty and Switch to a Protease Inhibitor-Sparing Regimen in an HIV-Positive Woman with Highly Active Antiretroviral Therapy-Associated Massive Breast EnlargementClinical Evaluation and Management of Metabolic and Morphologic Abnormalities Associated with Human Immunodeficiency VirusSíndrome de lipodistrofia asociado a la infección por el virus de la inmunodeficiencia humana (II). Aspectos clínicos y terapéuticosLipodistrofiasGrowth Hormone Treatment in Children and AdolescentsClinical perspectives on HIV-associated lipodystrophy syndrome: an updateMetabolic complications associated with antiretroviral therapyStrategies for treating HIV-related lipodystrophyAdverse effects of antiretroviral therapyPotential of Recombinant Human Growth Hormone in HIV-Associated Adipose Redistribution SyndromeCurrent review of the metabolic and endocrine disturbances in human immunodeficiency virus infectionCurrent review of the metabolic and endocrine disturbances in human immunodeficiency virus infectionIndinavir 17 August 1999Volume 131, Issue 4Page: 313-314KeywordsAdipose tissueBody weightComputed axial tomographyFatsHuman growth hormoneProtease inhibitor therapyProtease inhibitorsProteasesRetinitisViral load Issue Published: 17 August 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ..." @default.
• W2079571840 created "2016-06-24" @default.
• W2079571840 creator A5029582159 @default.
• W2079571840 creator A5032532307 @default.
• W2079571840 creator A5064111819 @default.
• W2079571840 date "1999-08-17" @default.
• W2079571840 modified "2023-10-11" @default.
• W2079571840 title "Reversal of Protease Inhibitor–Related Visceral Abdominal Fat Accumulation with Recombinant Human Growth Hormone" @default.
• W2079571840 cites W1974863148 @default.
• W2079571840 cites W2049954319 @default.
• W2079571840 cites W2142144836 @default.
• W2079571840 doi "https://doi.org/10.7326/0003-4819-131-4-199908170-00024" @default.
• W2079571840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10454960" @default.
• W2079571840 hasPublicationYear "1999" @default.
• W2079571840 type Work @default.
• W2079571840 sameAs 2079571840 @default.
• W2079571840 citedByCount "36" @default.
• W2079571840 countsByYear W20795718402016 @default.
• W2079571840 crossrefType "journal-article" @default.
• W2079571840 hasAuthorship W2079571840A5029582159 @default.
• W2079571840 hasAuthorship W2079571840A5032532307 @default.
• W2079571840 hasAuthorship W2079571840A5064111819 @default.
• W2079571840 hasConcept C126322002 @default.
• W2079571840 hasConcept C141071460 @default.
• W2079571840 hasConcept C142462285 @default.
• W2079571840 hasConcept C159047783 @default.
• W2079571840 hasConcept C2522874641 @default.
• W2079571840 hasConcept C2775967933 @default.
• W2079571840 hasConcept C2776452011 @default.
• W2079571840 hasConcept C2777210460 @default.
• W2079571840 hasConcept C2777447569 @default.
• W2079571840 hasConcept C2777869810 @default.
• W2079571840 hasConcept C2779889181 @default.
• W2079571840 hasConcept C2780216070 @default.
• W2079571840 hasConcept C2780593183 @default.
• W2079571840 hasConcept C2780727368 @default.
• W2079571840 hasConcept C2781160516 @default.
• W2079571840 hasConcept C2781432083 @default.
• W2079571840 hasConcept C2993143319 @default.
• W2079571840 hasConcept C3013748606 @default.
• W2079571840 hasConcept C71924100 @default.
• W2079571840 hasConcept C90924648 @default.
• W2079571840 hasConceptScore W2079571840C126322002 @default.
• W2079571840 hasConceptScore W2079571840C141071460 @default.
• W2079571840 hasConceptScore W2079571840C142462285 @default.
• W2079571840 hasConceptScore W2079571840C159047783 @default.
• W2079571840 hasConceptScore W2079571840C2522874641 @default.
• W2079571840 hasConceptScore W2079571840C2775967933 @default.
• W2079571840 hasConceptScore W2079571840C2776452011 @default.
• W2079571840 hasConceptScore W2079571840C2777210460 @default.
• W2079571840 hasConceptScore W2079571840C2777447569 @default.
• W2079571840 hasConceptScore W2079571840C2777869810 @default.
• W2079571840 hasConceptScore W2079571840C2779889181 @default.
• W2079571840 hasConceptScore W2079571840C2780216070 @default.
• W2079571840 hasConceptScore W2079571840C2780593183 @default.
• W2079571840 hasConceptScore W2079571840C2780727368 @default.
• W2079571840 hasConceptScore W2079571840C2781160516 @default.
• W2079571840 hasConceptScore W2079571840C2781432083 @default.
• W2079571840 hasConceptScore W2079571840C2993143319 @default.
• W2079571840 hasConceptScore W2079571840C3013748606 @default.
• W2079571840 hasConceptScore W2079571840C71924100 @default.
• W2079571840 hasConceptScore W2079571840C90924648 @default.
• W2079571840 hasIssue "4" @default.
• W2079571840 hasLocation W20795718401 @default.
• W2079571840 hasLocation W20795718402 @default.
• W2079571840 hasOpenAccess W2079571840 @default.
• W2079571840 hasPrimaryLocation W20795718401 @default.
• W2079571840 hasRelatedWork W1971285076 @default.
• W2079571840 hasRelatedWork W1996622637 @default.
• W2079571840 hasRelatedWork W2053286376 @default.
• W2079571840 hasRelatedWork W2079948480 @default.
• W2079571840 hasRelatedWork W2089124181 @default.
• W2079571840 hasRelatedWork W2132421451 @default.
• W2079571840 hasRelatedWork W2160775945 @default.
• W2079571840 hasRelatedWork W2313444624 @default.
• W2079571840 hasRelatedWork W2374691723 @default.
• W2079571840 hasRelatedWork W2401714398 @default.
• W2079571840 hasVolume "131" @default.
• W2079571840 isParatext "false" @default.
• W2079571840 isRetracted "false" @default.
• W2079571840 magId "2079571840" @default.
• W2079571840 workType "article" @default.